BiomX Inc. Files 8-K/A Amendment on Director and Officer Changes

TL;DR

BiomX filed an 8-K/A amendment on director/officer changes and compensation, effective March 14, 2024.

AI Summary

BiomX Inc. filed an amendment (Amendment No. 1) to its Form 8-K on March 21, 2024, reporting changes related to its board of directors and executive compensation. The filing specifically addresses the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers. The earliest event reported in this amendment was on March 14, 2024.

Why It Matters

This amendment provides updated information on the composition of BiomX Inc.'s leadership and their compensation, which can be crucial for investors assessing corporate governance and potential strategic shifts.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and concerns routine corporate governance matters, not a significant financial event.

Key Numbers

• 001-38762 — SEC File Number (BiomX Inc.'s SEC filing identifier)

Key Players & Entities

• BiomX Inc. (company) — Registrant
• March 14, 2024 (date) — Earliest event reported
• March 21, 2024 (date) — Filing date of amendment
• Delaware (jurisdiction) — State of Incorporation

FAQ

Key Financial Figures

• $0.0001 — onsisting of one share of Common Stock, $0.0001 par value , and one Warrant entitling t

Filing Documents

• ea0202300-8ka1_bio.htm (8-K/A) — 40KB
• 0001213900-24-024771.txt ( ) — 255KB
• phge-20240320.xsd (EX-101.SCH) — 4KB
• phge-20240320_def.xml (EX-101.DEF) — 26KB
• phge-20240320_lab.xml (EX-101.LAB) — 36KB
• phge-20240320_pre.xml (EX-101.PRE) — 25KB
• ea0202300-8ka1_bio_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A ( Amendment No. 1 ) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 22 Einstein St. , Floor 4 Ness Ziona , Israel 7414003 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: + 972 723942377 n/a (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one share of Common Stock, $0.0001 par value , and one Warrant entitling the holder to receive one half share of Common Stock PHGE.U NYSE American Shares of Common Stock, $0.0001 par value PHGE NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On March 18, 2024, BiomX Inc. (the "Company") filed a Current Report on Form 8-K (the "Original 8-K") reporting the appointment of Dr. Jesse Goodman, Jonathan Leff and Gregory Merril (collectively, the "New Directors") to serve on the Company's Board of Directors (the "Board") effective as of March 15, 2024. At the time of filing the Original 8-K, the Board committee assignments for the New Directors had not been determined. In accordance with instruction no. 2 of the Instructions to Item 5.02 of Form 8-K, the Company is filing this Amendment No. 1 to the Original 8-K (this "Amendment No. 1") to report that, on March 20, 2024, the Board appointed (i) Dr. Goodman and Mr. Merril to the Nominating and Corporate Governance Committee and (ii) Mr. Leff to the Compensation Committee, effective immediately. Except as expressly set forth herein, this Amendment No. 1 does not amend the Original 8-K in any way and does not modify or update any other disclosures contained in the Original 8-K. This Amendment No. 1 supplements the Original 8-K and should be read in conjunction with the Original 8-K. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMX INC. March 21, 2024 By: /s/ Jonathan Solomon Name: Jonathan Solomon Title: Chief Executive Officer 2

View Full Filing

View this 8-K/A filing on SEC EDGAR